Craniopharyngioma, Child
0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Day One BiopharmaceuticalsCA - Brisbane
1 programTovorafenibPHASE_2Small Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Day One BiopharmaceuticalsTovorafenib
Colorado TherapeuticsTumor and Blood Specimens
Clinical Trials (2)
Total enrollment: 307 patients across 2 trials
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
Start: Sep 2022Est. completion: Mar 202857 patients
Phase 2Recruiting
Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
Start: Mar 2019Est. completion: Dec 2030250 patients
N/AEnrolling By Invitation
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 307 patients
Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.